cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eiger Biopharmaceuticals Inc
2 own
10 watching
Current Price
$1.9
$0.25
(15.15%)
logo-eigr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
83.69M
52-Week High
52-Week High
10.0213
52-Week Low
52-Week Low
0.96
Average Volume
Average Volume
1.5M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization83.69M
icon52-Week High10.0213
icon52-Week Low0.96
iconAverage Volume1.5M
iconDividend Yield--
iconP/E Ratio--
What does the Eiger Biopharmaceuticals Inc do?
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Read More
How much money does Eiger Biopharmaceuticals Inc make?
News & Events about Eiger Biopharmaceuticals Inc.
PR Newswire
23days ago
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm PR Newswire LOS...
Globe Newswire
23days ago
LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ...
Business Wire
23days ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (Eiger or the Company) (NASDAQ: EIGR) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise...
Business Wire
25days ago
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Eiger Biopharmaceuticals, Inc. (Eiger or the Company) (NASDAQ: EIGR) in the United States District Court of Northern California on behalf of...
PR Newswire
26days ago
EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 PR Newswire NEW YORK, Jan. 6, 2023 NEW YORK, Jan. 6, 2023 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Eiger Biopharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Eiger Biopharmaceuticals Inc shares?
plus_minus_icon
How can I buy Eiger Biopharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Eiger Biopharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eiger Biopharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What percentage is Eiger Biopharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eiger Biopharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.9
$0.25
(15.15%)
logo-eigr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.93
$0.01 (0.52 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.17
$0.10 (4.83 %)
ONCOCYTE CORP
ONCOCYTE CORP
$0.39
$-0.01 (-2.92 %)
CEL-SCI Corp
CEL-SCI Corp
$2.62
$0.05 (1.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
RETRACTABLE TECHNOLOGIES INC
RETRACTABLE TECHNOLOGIES INC
$1.93
$0.01 (0.52 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.17
$0.10 (4.83 %)
ONCOCYTE CORP
ONCOCYTE CORP
$0.39
$-0.01 (-2.92 %)
CEL-SCI Corp
CEL-SCI Corp
$2.62
$0.05 (1.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00